Shots:

• Alnylam to add an additional investigational product through the end of IND-enabling studies in Sanofi’s subsidiary Genzyme and Alnylam in 2014 deal- where companies collaborated to develop and commercialize RNAi therapeutics for undisclosed rare disease
• Sanofi to take care of clinical development and commercialization of a product. Post-approval Alnylam to receive royalties on WW sales from Sanofi. Additionally- Sanofi agreed to release the shares of Alnylam (12% acquired at $80/share- in 2014)
• In 2012- the companies initially collaborated to develop RNAi therapies including ALN-TTR02 (Patisiran) & ALN-TTRsc02 (Vutrisiran) for ATTR in Japan & Asia. In 2018- the companies further restructured the 2014 alliance with the addition of Fitusiran

Ref: Sanofi | Image: Behance